Revenue Performance - The total revenue for the year ended December 31, 2023, was approximately RMB 1,763.7 million, a decrease of 18.2% from RMB 2,156.9 million in 2022[1]. - The Fluid and Bioprocess Systems segment reported revenue of approximately RMB 611.3 million, down 30.4% from RMB 878.6 million in 2022, primarily due to a decrease in uncompleted contracts and order volume[2]. - The Cleanroom and Automation Control and Monitoring Systems segment saw revenue decline by 14.2% to approximately RMB 441.2 million from RMB 514.1 million, mainly due to a drop in order volume in 2023[3]. - The Powder Solid Systems segment experienced a revenue increase of 2.4%, reaching approximately RMB 251.8 million, attributed to a higher number of uncompleted contracts at the beginning of the year[5]. - The GMP Compliance Services segment's revenue decreased by 4.5% to approximately RMB 90.1 million from RMB 94.3 million, due to a reduction in order volume and lower conversion rates of COVID-19 related projects[6]. - The Life Science Consumables segment reported a revenue decline of 21.9% to approximately RMB 303.4 million from RMB 388.3 million, primarily due to decreased order volume in 2023[7]. - The Pharmaceutical Equipment Distribution and Agency segment saw a significant revenue increase of 84.0%, reaching approximately RMB 65.9 million from RMB 35.8 million, driven by an increase in uncompleted contracts and improved project execution efficiency[8]. Profitability and Financial Performance - The gross profit for the year was approximately RMB 336.1 million, a decrease of 31.2% from RMB 488.8 million in 2022, reflecting the decline in revenue[12]. - The gross profit margin for the year was 19.1%, down from 22.7% in the previous year[38]. - The company reported a loss attributable to owners of RMB 32.6 million from continuing operations, compared to a profit of RMB 104.2 million in the previous year[40]. - The total comprehensive income attributable to the company's owners for the year ended December 31, 2023, was RMB (123,931) thousand, compared to RMB 114,965 thousand for the year ended December 31, 2022, reflecting a significant decline[71]. - The company reported a net loss from continuing operations of RMB (43,065) thousand for the year ended December 31, 2023, compared to a loss of RMB (80,866) thousand for the previous year[71]. - The company reported a basic loss per share of RMB (32,607) for the year ended December 31, 2023, compared to a profit of RMB 104,237 for the year ended December 31, 2022[151]. Assets and Liabilities - The total assets decreased to RMB 2,158.97 million from RMB 2,388.76 million in the previous year[38]. - Total liabilities decreased from RMB 1,505,182 thousand in 2022 to RMB 1,383,499 thousand in 2023, a reduction of approximately 8.1%[94]. - Current assets decreased to RMB 1,573,819 thousand as of December 31, 2023, from RMB 1,801,007 thousand as of December 31, 2022, indicating a reduction of approximately 12.6%[72]. - The total equity attributable to the company's owners was RMB 775,473 thousand as of December 31, 2023, down from RMB 883,581 thousand as of December 31, 2022, reflecting a decrease of about 12.2%[72]. - Non-current assets totaled RMB 585,153 thousand as of December 31, 2023, slightly down from RMB 587,756 thousand as of December 31, 2022[72]. Research and Development - Research and development expenses decreased by RMB 14.9 million or 21.1% to approximately RMB 55.3 million, primarily due to a reduction in workforce and material consumption[65]. - The company is actively involved in the research and commercialization of new therapies, which is a key growth driver for its business[33]. - The company has introduced more cell-related equipment and systems in the ATMP industry in 2023, leveraging its proprietary intellectual property[35]. Market and Industry Outlook - The company is optimistic about the mid to long-term trends in the cell and gene therapy industry despite a recent slowdown in investment in China[35]. - The market for GLP-1 drugs is expected to continue driving research and production investments for several years, indicating a strong future outlook for the pharmaceutical industry[169]. - The expansion of production capacity for oral anti-tumor formulations and related CDMO services is creating new business opportunities in engineering technology systems[170]. - The company anticipates significant growth potential for domestic pharmaceutical service providers due to competitive pricing, stable supply chains, and effective after-sales service[171]. Operational Highlights - The company has classified assets held for sale at RMB 8,590 thousand as of December 31, 2023, with no comparable figure for the previous year[72]. - The company has been actively investing in human resources, regional expansion, and enhancing product and application solution capabilities, expecting to achieve more satisfactory business results[179]. - The company participated in and organized 55 events in 2023, including 16 exhibitions and 26 industry conferences, to enhance brand visibility[194].
奥星生命科技(06118) - 2023 - 年度业绩